CRACKING CANCER ANEUPLOIDY
Our lab focuses on a unique, understudied trait of cancer. Changes in the chromosomal composition of the cell, also known as aneuploidy, make for a fundamental difference between normal and cancer cells. We combine experimental and computational approaches to uncover the basic biology underlying this hallmark of cancer, track its origins and understand its cellular consequences. By doing so, we strive to expand our understanding of the genetic basis of cancer, and to make aneuploidy a therapeutic target for precision cancer medicine.
OUR RESEARCH INTERESTS
Aneuploidy – the presence of an abnormal number of chromosomes in cancer cells — is characteristic of most tumors, and is rarely observed in normal tissues. It is not fully understood how aneuploidy contributes to tumor formation and progression. Moreover, there are currently no therapeutics that target this hallmark of cancer to eliminate tumors. We apply a variety of genomic and functional approaches to studying this phenomenon.
EVOLUTION OF CANCER MODELS
The study of the complex genetics of human cancer depends on reliable cancer model systems. However, these models reflect the biology of actual human tumors only to a certain extent, and they evolve in ways that pose both risks and opportunities for cancer research. We study the genomic stability and evolution of cancer model systems, in order to improve their use in basic research, with an emphasis on aneuploidy research.
STEM CELLS & CANCER
Human stem cells share fundamental characteristics with human cancer cells, and thus make for a unique model system for the study of cancer genetics. We use human stem cells as a tool for aneuploidy research, taking advantage of their inherent chromosomal instability and of their amenability to genome editing. We also use human stem cells as a tool for the identification of cancer vulnerabilities.
OUR BIG QUESTIONS
WHAT DRIVES ANEUPLOIDY IN CANCER? HOW DOES ANEUPLOIDY CONTRIBUTE TO THE INITIATION AND PROGRESSION OF TUMORS?
WHAT CELLULAR VULNERABILITIES ARE INDUCED BY ANEUPLOIDY? HOW CAN ANEUPLOIDY BE EXPLOITED TO KILL CANCER CELLS?
WHAT ARE THE IMPLICATIONS OF GENOMIC EVOLUTION FOR CANCER MODELING? HOW CAN CANCER MODEL SYSTEMS BE IMPROVED?
THE ISF HAS AWARDED THE BEN-DAVID LAB THE ISF RESEARCH GRANT AND THE ISF NEW FACULTY EQUIPMENT GRANT!
July 27, 2021
WELCOME TO THE LAB, YONATAN AND LINOY!
June 27, 2021
April 1, 2021
NEW GRANTS AWARDED TO THE LAB:
* THE FORBECK FOUNDATION COVID RECOVERY GRANT
* THE SCHREIBER FOUNDATION RESEARCH GRANT
* THE SHTACHER AWARD
February 25, 2021
OUR NEW STUDY ON ANEUPLOIDY-INDUCED VULNERABILITIES JUST PUBLISHED IN NATURE! YOU CAN READ IT HERE.
January 27, 2021
OUR NEW PREPRINT ON THE GENOMIC EVOLUTION OF PDXS IS OUT -- READ IT HERE.
January 18, 2021
CHECK OUT DR. BEN-DAVID'S POPULAR SCIENCE TALK AT THE ICRF WEBINAR SERIES
January 14, 2021
OUR PAPER ON "ANEUPLOIDY-INDUCED CANCER VULNERABILITY TO MITOTIC CHECKPOINT INHIBITION" HAS BEEN ACCEPTED TO NATURE! CONGRATS!
Nov 19, 2020
CONGRATS TO MICHAL AND TO KAVYA, FOR SHARING THE SECOND PRIZE OF THE "BEST POSTER AWARD" OF THE SAFRA BIOINFORMATICS RETREAT!
Nov 4, 2020
WELCOME TO ELI AND SHOSHI, WHO ARE JOINING OUR LAB THIS WEEK!
Nov 1, 2020
CONGRATULATIONS TO TOM AND TO GIL, FOR OFFICIALLY STARTING THEIR PHD PROGRAM!
Oct 1, 2020
THE BEN-DAVID LAB IS AWARDED THE ERC STARTING GRANT! SEE HERE FOR THE PRESS RELEASE.
September 03, 2020
DR. BEN-DAVID IS AWARDED THE ICRF GESHER AWARD!
August 21, 2020
DR. BEN-DAVID (TAU) AND DR. AMON (MIT) ARE AWARDED A JOINT BSF RESEARCH GRANT!
July 26, 2020
OUR CAS9/P53 ARTICLE IS FEATURED ON THE COVER OF NATURE GENETICS THIS MONTH! CHECK IT OUT HERE.
July 7, 2020
WELCOME TO GIL, WHO'S JUST JOINED OUR LAB AS A SUMMER STUDENT! AND CONGRATS TO JOHANNA FOR OFFICIALLY STARTING HER PHD!
July 1, 2020
THE BEN-DAVID LAB IS AWARDED THE DOD CANCER RESEARCH PROGRAM CAREER DEVELOPMENT AWARD!
June 22, 2020
June 11, 2020
May 18, 2020
DR. BEN-DAVID IS AWARDED THE 2020 'NEXT GEN STAR' AWARD OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)
March 1, 2020
WATCH DR. BEN-DAVID'S TALK AT:
February 3, 2020